Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer
Main Article Content
Keywords
bladder cancer, consolidative surgery, cystectomy, metastatic
Abstract
The effect of radical cystectomy and extended pelvic lymph node dissection (RC/PLND) on the survival of patients with locally advanced and/or regionally metastatic bladder cancer is unknown. However, emerging evidence suggests that there may be survival benefit to a subset of select patients with this disease who demonstrate a response to chemotherapy. This article will review the current literature on the role of RC/PLND in the consolidative treatment of locally advanced and regionally metastatic bladder cancer.
Metrics
Metrics Loading ...
References
[1] Facts C. American Cancer Society: Cancer Facts and Figures 2015 2015.
[2] Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414–22.
[3] Stein BJP, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S, et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer : Long-Term Results in 1 , 054 Patients 2011;19:666–75.
[4] Bellmunt J, Von Der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 2012;30:1107–13.
[5] Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111–6.
[6] Madersbacher S. Radical Cystectomy for Bladder Cancer Today--A Homogeneous Series Without Neoadjuvant Therapy. J Clin Oncol 2003;21:690–6.
[7] Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003;97:2425–31.
[8] Mills RD, Turner WH, Fleischmann a, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19–23.
[9] Herr H, Lee C, Chang S, Lerner S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol 2004;171:1823–8.
[10] Herr HW, Donat SM, Thompson IM. Re: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy [4] (multiple letters). J Urol 2001;166:630.
[11] Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449–54.
[12] Babaian RJ, Johnson DE, Llamas L, Ayala a G. Metastases from transitional cell carcinoma of urinary bladder. Urology 1980;16:142–4.
[13] von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068-77.
[14] von der Maase H, Sengelov L. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. J Clin Oncol 2005;23:4602–8.
[15] Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey J a, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–81.
[16] Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 1994;151:598–600; discussion 600–1.
[17] Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 1993;150:65–9.
[18] Dodd BPM, Mccaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, et al. Outcome of Postchemotherapy Surgery After Treatment With Metho trexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma 1999;17:2546–52.
[19] Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811–4.
[20] de Vries RR, Nieuwenhuijzen J a, Meinhardt W, Bais EM, Horenblas S. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol 2009;35:352–5.
[21] Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway C a, et al. Is There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder? J Urol 2003;169:2113–7.
[22] Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–9.
[23] Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol Semin Orig Investig 2015:1–8.
[24] Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The MD Anderson Experience. J Urol 2004;171:145-8
[25] Svatek RS, Siefker-Radtke AO, Dinney CP Management of metastatic urothelial cancer: the role of surgery as a adjunct to chemotherapy Can. Urol. Assoc J 2009: 3(Suppl4):S228-31。
[26] Abe T, Shinohara N, Harabayashi T, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer Eur Urol 2007;52:1106-13
[27] Buy JN, Moss AA, Guinet C, et al: MR staging of bladder carcinoma: correlation with pathologic findings. Radiology 1988; 169: 695–700.
[28] Lantz EJ and Hattery RR: Diagnostic imaging of urothelial cancer. Urol. Clin. North Am. 1984; 11: 567–83.
[29] Yaman O, Baltaci S, Arikan N, et al: Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br. J. Urol. 1996; 78: 197–200.
[30] Voges GE, Tauschke E, Stöckle M, et al: Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J. Urol. 1989; 142: 972–4.
[31] Scolieri MJ, Paik ML, Brown SL, et al: Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 2000; 56: 930–4.
[32] Sternberg CN, Pansadoro V, Calabrò F, et al: Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97: 1644–52.
[33] Kibel AS, Dehdashti F, Katz MD, et al: Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314–4320.
[34] Swinnen G, Maes A, Pottel H, et al: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 2010; 57: 641–7.
[35] Apolo AB, Riches J, Schöder H, et al: Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J. Clin. Oncol. 2010; 28: 3973–8.
[36] Schöder H, Ong SC, Reuter VE, et al: Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol. Imaging Biol. 2012; 14: 245–51.
[37] Mertens LSL, Fioole-Bruining A, van Rhijn BWG, et al: FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer. J. Urol. 2013; 189: 1687–91.
[38] Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 2016; 387: 1909–20.
[2] Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414–22.
[3] Stein BJP, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S, et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer : Long-Term Results in 1 , 054 Patients 2011;19:666–75.
[4] Bellmunt J, Von Der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 2012;30:1107–13.
[5] Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111–6.
[6] Madersbacher S. Radical Cystectomy for Bladder Cancer Today--A Homogeneous Series Without Neoadjuvant Therapy. J Clin Oncol 2003;21:690–6.
[7] Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003;97:2425–31.
[8] Mills RD, Turner WH, Fleischmann a, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19–23.
[9] Herr H, Lee C, Chang S, Lerner S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol 2004;171:1823–8.
[10] Herr HW, Donat SM, Thompson IM. Re: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy [4] (multiple letters). J Urol 2001;166:630.
[11] Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449–54.
[12] Babaian RJ, Johnson DE, Llamas L, Ayala a G. Metastases from transitional cell carcinoma of urinary bladder. Urology 1980;16:142–4.
[13] von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068-77.
[14] von der Maase H, Sengelov L. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. J Clin Oncol 2005;23:4602–8.
[15] Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey J a, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–81.
[16] Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 1994;151:598–600; discussion 600–1.
[17] Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 1993;150:65–9.
[18] Dodd BPM, Mccaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, et al. Outcome of Postchemotherapy Surgery After Treatment With Metho trexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma 1999;17:2546–52.
[19] Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811–4.
[20] de Vries RR, Nieuwenhuijzen J a, Meinhardt W, Bais EM, Horenblas S. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol 2009;35:352–5.
[21] Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway C a, et al. Is There a Therapeutic Role for Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Metastatic Transitional Cell Carcinoma of the Bladder? J Urol 2003;169:2113–7.
[22] Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–9.
[23] Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol Semin Orig Investig 2015:1–8.
[24] Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The MD Anderson Experience. J Urol 2004;171:145-8
[25] Svatek RS, Siefker-Radtke AO, Dinney CP Management of metastatic urothelial cancer: the role of surgery as a adjunct to chemotherapy Can. Urol. Assoc J 2009: 3(Suppl4):S228-31。
[26] Abe T, Shinohara N, Harabayashi T, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer Eur Urol 2007;52:1106-13
[27] Buy JN, Moss AA, Guinet C, et al: MR staging of bladder carcinoma: correlation with pathologic findings. Radiology 1988; 169: 695–700.
[28] Lantz EJ and Hattery RR: Diagnostic imaging of urothelial cancer. Urol. Clin. North Am. 1984; 11: 567–83.
[29] Yaman O, Baltaci S, Arikan N, et al: Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br. J. Urol. 1996; 78: 197–200.
[30] Voges GE, Tauschke E, Stöckle M, et al: Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J. Urol. 1989; 142: 972–4.
[31] Scolieri MJ, Paik ML, Brown SL, et al: Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 2000; 56: 930–4.
[32] Sternberg CN, Pansadoro V, Calabrò F, et al: Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97: 1644–52.
[33] Kibel AS, Dehdashti F, Katz MD, et al: Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314–4320.
[34] Swinnen G, Maes A, Pottel H, et al: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 2010; 57: 641–7.
[35] Apolo AB, Riches J, Schöder H, et al: Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J. Clin. Oncol. 2010; 28: 3973–8.
[36] Schöder H, Ong SC, Reuter VE, et al: Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol. Imaging Biol. 2012; 14: 245–51.
[37] Mertens LSL, Fioole-Bruining A, van Rhijn BWG, et al: FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer. J. Urol. 2013; 189: 1687–91.
[38] Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 2016; 387: 1909–20.
Article Sidebar
Published
Aug 31, 2016
Article Details
How to Cite
Tyson, M. D., Chang, S. S., & Keegan, K. A. (2016). Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer. Bladder, 3(2), e26. https://doi.org/10.14440/bladder.2016.89
Issue
Section
Reviews
Authors who publish with the Bladder agree to the following terms:
- Authors retain copyright and grant the Bladder right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
